These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38932429)

  • 1. Immune Checkpoint Inhibitors-Induced Endocrinopathies: Assessment, Management and Monitoring in a Comprehensive Cancer Centre.
    Elshafie O; Khalil AB; Salman B; Atabani A; Al-Sayegh H
    Endocrinol Diabetes Metab; 2024 Jul; 7(4):e00505. PubMed ID: 38932429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival.
    Yang L; Murthy S; Cortellini A; Lim EA; Gonzalez M; Pinato DJ; Abdel-Malek M; Mahmoud S; Martin NM
    Front Endocrinol (Lausanne); 2024; 15():1369268. PubMed ID: 38681767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
    Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
    J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center.
    Barlas T; Sutcuoglu O; Akdogan O; Balos Toruner F; Akturk M; Ozdemir N; Yazici O; Eroglu Altinova A
    Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39194584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
    Santos MJ
    Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
    Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
    J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
    Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
    Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
    Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
    Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study.
    Gao R; Li C; Zhang S; Liao N; Guan H
    Endocrine; 2024 Sep; 85(3):1446-1455. PubMed ID: 38951449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrinopathies Associated With Immune Checkpoint Inhibitor Use.
    Kotwal A; Kennedy R; Kikani N; Thosani S; Goldner W; Shariff A
    Endocr Pract; 2024 Jun; 30(6):584-591. PubMed ID: 38554775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
    Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
    J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
    Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction.
    González MM; Sanz-Pastor AG; Gómez RÁ; Torrecilla NB; Moreno DM; Fernández LG; Rivas AM; Guerra AL; Álvarez R; Arranz JÁ; Rodas IM; Escudero V; Sanjurjo M; Vallejo JM; Martín M; Albarrán OG
    Endocr Metab Immune Disord Drug Targets; 2024; 24(14):1628-1639. PubMed ID: 38362680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
    Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
    Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
    [No Abstract]   [Full Text] [Related]  

  • 17. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 18. Endocrine toxicities of immune checkpoint inhibitors.
    Wright JJ; Powers AC; Johnson DB
    Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.